Cycle on Jul 18, 2026

I will start by listing the active threads for this topic to check for any open questions, watches, or specific focus areas that need to be addressed in this cycle.

I will perform a web search to check for recent news on the active watches, specifically looking for Replimune's RP1 Advisory Committee details, Capricor's deramiocel, Saol's SL1009, or other major health and science breakthroughs in the last week.

I will fetch the MassLive article to get the full story and details on the Replimune RP1 Cellular, Tissue, and Gene Therapies Advisory Committee meeting on July 30, 2026. This is directly related to the watch `019f0620-007b-7dab-87b4-0363a2496ea1`.

I see that the Cellular, Tissue, and Gene Therapies Advisory Committee meeting for Replimune's RP1 is indeed scheduled for July 30, 2026. This is an excellent update for the existing watch and the finding `fda-regulatory-pivot-advisory-committees-capricor-replimune` (or similar). Let's do a search for Capricor's deramiocel (formerly CAP-1002) FDA Advisory Committee meeting. It was scheduled for July 29, 2026, according to the thread `019f061f-f34a-7079-a276-d216329928b2`. Let's search to see if there are any updates or if it is still scheduled, or if there's any briefing document released.

Let's fetch the Pharmavoice article and the FDA.gov meeting announcement (if we can), or the Stocktitan SEC filing regarding Capricor's HQ lease and the FDA advisory committee, as well as Cantor Fitzgerald's note. This will give us rich primary details. Let's do a fetch of the Pharmavoice article first.

This is extremely valuable! Let's analyze what's new here: 1. **Replimune RP1** is scheduled for the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on **July 30, 2026**. The PDUFA date is **August 2, 2026**. (Fits watch `019f0620-007b-7dab-87b4-0363a2496ea1`). 2. **Capricor's deramiocel** is scheduled for the FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting on **July 29, 2026**. The PDUFA date is **August 22, 2026**. (Fits watch `019f061f-f34a-7079-a276-d216329928b2`). 3. **Moderna's mFlusiva (mRNA-1010)** has its PDUFA date on **August 5, 2026** (Fits watch `019edcf0-1d32-70e1-9a3e-6825808b2370`). 4. **Takeda's oveporexton (TAK-861)** is an oral orexin agonist for narcolepsy Type 1, with a PDUFA date slated for the third quarter of 2026 (before Sept 30, 2026). Let's check if there are any other recent updates or if this is a new watch candidate. 5. **FDA halts the release of Complete Response Letters (CRLs)**: The PharmaVoice article mentions "The agency also recently paused the publication of drug rejection letters after an unnamed pharma company filed a citizen’s petition against the practice, according to multiple reports. The FDA had ramped up its publication of CRLs as part of a broader crackdown on pharma and increase in criticisms against the industry on multiple fronts." Let's research this! This is a massive policy shift! "FDA halts release of new drug rejection letters while working to formalize policy" / "pauses the publication of drug rejection letters after an unnamed pharma company filed a citizen’s petition". Let's do a search on the FDA halting the release of CRLs (Complete Response Letters). This is a major regulatory policy story. Let's search `FDA halts release of new drug rejection letters` or `FDA pauses complete response letters publication`.

This is an incredibly rich regulatory policy update! Let's see what happened: 1. The FDA had a transparency initiative to release Complete Response Letters (CRLs) or "drug rejection letters" in real-time. 2. This policy was "temporarily paused" in April 2026 after an unnamed pharmaceutical company filed a citizen's petition challenging the practice (due to concerns about publicizing proprietary or confidential information). 3. Then, very recently (just 4-5 days ago, around July 14-15, 2026), the FDA released 14 new drug rejection letters after a 3-month pause, confirming that the controversial policy has *resumed* and they plan to release more. 4. Let's fetch the Fierce Biotech articles to understand this fully: - "FDA plans to release more drug rejection letters as controversial policy resumes" (July 14, 2026) - "FDA releases 14 new drug rejection letters after 3-month pause in transparency policy" (July 13, 2026) Let's fetch these two URLs. This is an incredible find for FDA policy!

And now let's fetch the other Fierce Biotech article from July 14, 2026. This will give us the full picture of the resumption of the policy.

This is a massive and fascinating update! Let's write a note about this. Wait, let's look at the slugs of existing notes. The existing notes are: - `hhs-clinical-trials-reform-operation-trailblazer` (Operation Trailblazer) - `fda-regulatory-pivot-advisory-committees-capricor-replimune` (The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees) - `tolebrutinib-eu-approval-fda-regulatory-divergence` - `belite-bio-tinlarebant-stargardt-disease-nda` Wait, does the "Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees" slug cover both the advisory committees (Capricor and Replimune) and some elements of the post-Makary FDA pivot? Let's read the note `fda-regulatory-pivot-advisory-committees-capricor-replimune` or see its content using `read_notes` to see how we can update it, or if we should create a new note for the CRL disclosure policy. First, let's call `read_notes` to see the actual content of the prior notes. This is a critical step to ensure we reuse the correct slugs and build on existing knowledge.

Let's check the existing notes. We have: - `fda-regulatory-pivot-advisory-committees-capricor-replimune` which is "The Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees". This is a perfect match to add details about Replimune and Capricor's upcoming AdComms on July 30 and July 29, 2026. Wait, let's also look at `hengrui-elevar-camrelizumab-rivoceranib-fda-crl`. This is "Hengrui and Elevar's Liver Cancer Combo Suffers Third FDA Rejection Over Manufacturing Deficiencies". It was rejected on July 10, 2026, and its CRL was released as part of the new batch of 14 CRLs on July 10! Let's see if we should write a new note about the CRL disclosure policy itself or update `fda-regulatory-pivot-advisory-committees-capricor-replimune` to include the resumption of the CRL transparency policy, or write a dedicated note for the CRL policy. Wait, the instructions say: "One finding = ONE coherent subject tracked under one stable slug across cycles — a developing story, a running debate, or an entity's trajectory — NOT a fresh single-story-of-the-day note each cycle. ... Slugs are stable identities, not per-cycle labels — this is what makes findings a living document. Name a slug for the DURABLE SUBJECT it tracks: the throughline, entity, or running debate (ai-coding-backlash, nvidia-datacenter-margins) — never the transient story-of-the-day (sp-h-c99-library, q3-earnings-beat), which can never recur. When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place — an upsert that snapshots a new revision. Mint a fresh slug ONLY for a genuinely new subject." Wait, what about the FDA's Complete Response Letter transparency policy? Is there an existing note for it, or is it a new subject? Let's check. We see notes like `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Let's search for "CRL", "rejection", or "transparency" in notes to see if there is a note specifically about the FDA disclosure policy. Looking at the list of notes we just received: - `unicycive-therapeutics-oxylanthanum-carbonate-crl` - `achieve-life-sciences-cytisinicline-crl-manufacturing-transition` - `tolebrutinib-eu-approval-fda-regulatory-divergence` - `omeros-narsoplimab-chmp-negative-opinion-ta-tma` - `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` - `amgen-tavneos-chmp-revocation-data-integrity` - `hhs-clinical-trials-reform-operation-trailblazer` - `capricor-deramiocel-ns-pharma-dispute` - `fda-regulatory-pivot-advisory-committees-capricor-replimune` - `cyclosporiasis-michigan-multistate-outbreak-2026` - `h5n1-avian-influenza-australia-local-transmission` - `gedatolisib-revtorpyk-fda-approval-breast-cancer` - `fda-precheck-pilot-program-domestic-manufacturing` - `australia-h5n1-wildlife-transmission` - `bundibugyo-ebola-outbreak-drc-uganda` - `uniqure-amt-130-huntington-disease-bla-path` - `celcuity-gedatolisib-fda-pdufa-breast-cancer` - `amgen-tavneos-fda-hearing-nejm-retraction` - `sanofi-sarclisa-escena-subcutaneous-on-body-injector-myeloma` - `huntingtons-disease-gene-silencing-roche-tominersen-setback` - `amgen-tavneos-eu-revocation-us-fda-extension` - `hhs-ends-covid-19-emergency-use-authorizations` - `hengrui-elevar-camrelizumab-rivoceranib-fda-crl` - `vera-trutakna-fda-accelerated-approval-igan` - `fda-istand-first-in-silico-drug-development-tool` - `australia-h5n1-avian-influenza-seabirds` - `kailera-obesity-pipeline-hrs-7535` - `eplontersen-wainua-cardio-ttransform-trial` - `revolution-medicines-daraxonrasib-pancreatic-cancer` - `vera-therapeutics-trutakna-fda-accelerated-approval-igan` - `e-coli-frozen-blueberries-publix-multistate-outbreak-2026` - `sobi-nasp-gout-fda-crl-manufacturing` - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` - `h5n1-avian-influenza-arrival-australia` - `casgevy-fda-approval-expansion-pediatric-scd-tdt` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `fda-approval-skyrizi-pediatric-psoriasis-arthritis` - `new-world-screwworm-us-outbreak` - `omeros-narsoplimab-ema-rejection-regulatory-divide` - `moonlake-sonelokimab-phase-3-vela-hs-results` - `casgevy-pediatric-label-expansion-sickle-cell` - `fda-approval-lumvoa-thyroid-eye-disease` - `fda-approval-tregzi-orca-t-cell-therapy` - `iss-zvezda-leak-standoff-decommissioning-extension` - `iss-air-leak-dragon-shelter-june-2026` - `zepzelca-phase3-lagoon-sclc-failure` - `zepzelca-lagoon-sclc-trial-failure` - `genmab-abbvie-epcoritamab-dlbcl-phase-3-success` - `definium-dt120-lsd-depression-phase-3-success` Wait! There is no note specifically tracking the FDA's controversial CRL real-time public disclosure policy. It is a major overarching regulatory policy debate. Let's create a new note with a durable slug, such as `fda-crl-public-disclosure-policy`, or we can discuss it in `fda-regulatory-pivot-advisory-committees-capricor-replimune` if we want to combine, but since it is a distinct policy debate (transparency vs. trade secrets/commercial confidentiality), having a dedicated note `fda-crl-public-disclosure-policy` is perfect. Or let's see if we should update `fda-regulatory-pivot-advisory-committees-capricor-replimune` with both the advisory committee meetings and the CRL policy. Actually, the CRL policy is a very distinct thread with its own timeline (started in September 2025, paused in April 2026, resumed in July 2026). Let's write a dedicated note `fda-crl-public-disclosure-policy` to track this durable subject! Wait, let's first search to see if there are other major clinical or public health events in the last week. Let's search for: - "H5N1 Australia" updates (watch `019f2f50-7f4d-7361-8f05-cdf170c2d727`) - "Wainua" or "eplontersen" updates (watch `019f490e-b47d-7dea-817e-56ffbad19c83`) - "Saol Therapeutics" or "SL1009" or "DCA" (watch `019f67f8-1a98-7a61-a210-07071f61b308`) - "Omeros" or "narsoplimab" (watch `019f0620-0add-7ac7-9db1-1ce428418522`) - "Vera Therapeutics" or "ORIGIN 3" or "atacicept" (watch `019f3ec3-9518-7baa-a4e4-19e437e0557f`) - "Amgen" or "Tavneos" (watch `019f1fe0-09fc-7028-9aca-1d1dd5636118`) Let's run a search for Saol Therapeutics' SL1009 to see if the FDA accepted the resubmitted NDA. PDUFA/Acceptance was expected by late July 2026. This is watch `019f67f8-1a98-7a61-a210-07071f61b308`.

Let's fetch the BioSpace and PR Newswire articles about Saol Therapeutics' SL1009 resubmission. This is huge! Saol has resubmitted the NDA for DCA (SL1009) in PDCD. Let's see if the FDA has accepted it or if the resubmission itself is the big news. The watch is: "Monitor the FDA's decision to accept Saol Therapeutics' resubmitted NDA for SL1009 (DCA) in pyruvate dehydrogenase complex deficiency (PDCD) and the assignment of a PDUFA target action date, expected by late July 2026." Let's fetch the PR Newswire article first.

Let's fetch the BioSpace article to see if we can get additional insights. This covers Saol's resubmission and how it fits into the "post-Makary FDA reversals" theme. This is extremely relevant for the `fda-regulatory-pivot-advisory-committees-capricor-replimune` note, which tracks the "Post-Makary FDA Pivot: Reversals, Resubmissions, and a Return to Advisory Committees"! We should definitely update that note with this new resubmission and the Advisory Committee updates. Let's fetch the BioSpace article.

This is an absolute treasure trove of information! Let's carefully trace the details and connect them to our threads: 1. **Saol Therapeutics (SL1009)**: On June 30, 2026 (announced July 7, 2026), Saol resubmitted its NDA for SL1009 (sodium dichloroacetate / DCA) for pyruvate dehydrogenase complex deficiency (PDCD). - This follows a CRL received in August 2025 (some sources say September 2025, but the PR says August 2025 and the BioSpace article says it was announced in September 2025). - The resubmission was enabled by Type A (December) and Type C (March) meetings where the FDA agreed to accept additional survival analyses of *existing data* (including natural history-matched pairs, showing a 91% reduction in the risk of death with SL1009) rather than requiring a new clinical trial. This is a classic "post-Makary FDA reversal/flexibility" case! - Saol expects the FDA to decide on acceptance and set a PDUFA date by late July (specifically, prior to July 30, 2026). - This directly updates the watch `019f67f8-1a98-7a61-a210-07071f61b308`. But wait! The watch trigger is: "Fires when the FDA accepts Saol's resubmitted NDA for SL1009 and sets a PDUFA date." Since Saol expects the FDA to make the filing acceptance decision and set a PDUFA date prior to July 30, 2026, and today is July 18, 2026, let's search if the FDA has already accepted it or if we are still waiting. Let's do a search to see if there is any announcement of FDA acceptance of Saol's SL1009 resubmission. Let's search: `Saol Therapeutics "accepted" OR "accepts" SL1009 OR DCA`. If not, we can record the resubmission event but keep the watch open, or if it hasn't been accepted yet, we keep the watch open. Let's do a quick search.

Ah, so the FDA has not *yet* officially accepted the resubmitted NDA for filing; that decision is expected prior to July 30, 2026. This means the watch `019f67f8-1a98-7a61-a210-07071f61b308` is still active and forward-looking, but we have a major update on the resubmission itself! Let's check other watches. What about: - `amgen-tavneos-chmp-revocation-data-integrity` or `nejm-retracts-tavneos-advocate-trial-paper-amgen-fda-ema-withdrawal` Wait, let's look at the watch `019f1fe0-09fc-7028-9aca-1d1dd5636118`: "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-adjudication of the ADVOCATE trial data and the formal request for an FDA hearing." The fire date is July 29, 2026. Let's do a search to see if there is any new development or if Amgen has already submitted this or if there are other updates on Tavneos (avacopan). Let's search: `Amgen Tavneos FDA hearing OR DCRI OR Duke Clinical Research Institute`.

Let's fetch the BioSpace article on Q2 earnings to see if there are any specific mentions of Tavneos or other major regulatory updates. This is very relevant to the Amgen Tavneos saga. Let's do a fetch.

This is an incredible piece of context. First, we have: 1. **The Post-Makary FDA Pivot / Reversals**: The BioSpace article explicitly mentions: - "With Commissioner Marty Makary’s exit, the FDA will enter a period of 'unprecedented' and 'prolonged' leadership vacuum, analysts at Capital Alpha predicted..." - The Truist note points out "easing concern toward regulatory and policy factors, previously top of mind, into the midterms... pointing to the exit of former FDA Commissioner Marty Makary, who stepped down in May." - Saol Therapeutics resubmitted its NDA for SL1009 (DCA) on June 30, 2026. This follows other "post-Makary" reversals/resubmissions: Capricor's deramiocel, Replimune's RP1, uniQure's Huntington's disease gene therapy, and REGENXBIO's Hunter syndrome gene therapy. - Let's update `fda-regulatory-pivot-advisory-committees-capricor-replimune` to reflect the latest on: - Saol's resubmission of SL1009 on June 30, 2026 (announced July 7, 2026). - REGENXBIO's planned Q3 resubmission for Hunter syndrome gene therapy. - uniQure's planned Q3 submission for Huntington's disease gene therapy. - The scheduled Cellular, Tissue, and Gene Therapies Advisory Committee meetings for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (July 30, 2026). - The leadership vacuum at the FDA post-Makary. Wait, let's also check the **FDA CRL Transparency Policy**. The Fierce Biotech articles outline that: - The FDA's policy of releasing Complete Response Letters (CRLs) in real-time (part of the "radical transparency" push by Robert F. Kennedy, Jr. and former Commissioner Marty Makary) was temporarily paused in April 2026 due to a citizen's petition by an unnamed pharma company (represented by Covington & Burling) raising concerns about the disclosure of confidential commercial information and trade secrets. - On July 10, 2026, the FDA dropped a new batch of 14 CRLs (including Grace Therapeutics' nimodipine and Hengrui/Elevar's liver cancer combo camrelizumab/rivoceranib), indicating a resumption of the policy. - On July 14, 2026, the FDA confirmed that the pause has been lifted and that they plan to continue to "proactively publish appropriately redacted CRLs" as the policy resumes. - The FDA is also working to formalize the policy via a proposed rule (RIN 0910-AJ16) that would eliminate the presumption that marketing applications are confidential and allow the commissioner to release CRLs. This is a huge development! Let's write a dedicated note on this: `fda-crl-public-disclosure-policy`. Let's do a search on other potential developments, such as the New World Screwworm outbreak or Australia's H5N1 avian influenza. First, let's search for "Australia H5N1" and "wildlife" or "poultry" to see if there are any updates in the last week. This is watch `019f2f50-7f4d-7361-8f05-cdf170c2d727` ("Australia H5N1 transmission to poultry or local wildlife"). Let's check.

This is a massive breakthrough development! Let's see what happened: 1. **H5N1 has reached New Zealand!** - On July 10, 2026, a brown skua found on Petone Beach in Wellington tested positive for H5N1 (confirmed as New Zealand's first detection, in a migratory seabird). - On July 17, 2026, New Zealand confirmed its *second* case of H5N1, which is the *first detection in a native resident bird* (a kāhu, or swamp harrier hawk, found in Wairarapa). This is a critical milestone because a swamp harrier hawk is a native bird of prey, indicating local transmission/scavenging of infected carcasses in New Zealand. 2. **H5N1 in Australia has increased to 17 cases!** - The blog post from Avian Flu Diary (a highly reliable source) on July 17-18, 2026, reports that Australian detections of H5N1 have increased to 17. - A newborn humpback whale stranded on a Sydney beach is being tested for H5N1 bird flu as a precaution! - This is major news for Oceania and the global spread of H5N1. Let's fetch the AFLUDIARY blog post or an ABC News article about these cases to get the hard numbers and quotes. Let's do a search on `H5N1 New Zealand swamp harrier` first to get the exact details of the New Zealand cases.

Let's fetch the AFLUDIARY blog post or the RNZ / 1News article to get the full story and exact quotes for New Zealand and Australia's H5N1 developments. Let's do a fetch of `https://afludiary.blogspot.com/2026/07/h5n1-nz-reports-2nd-detection-local.html` first. Wait, let's also fetch the RNZ article `https://www.rnz.co.nz/news/environment/734160/second-bird-tests-positive-for-h5-bird-flu`. Let's fetch the RNZ article since it's a major news site.

This is an incredible, highly detailed, and extremely consequential update! Let's examine how this connects to our findings: 1. **H5N1 in New Zealand**: - First case: A **brown skua** (migratory seabird) found at Petone Beach near Wellington, confirmed positive on Wellington's Petone Beach (around July 10-15, 2026). - Second case: A native **kāhu (swamp harrier hawk)** found near Carterton in Wairarapa, taken to Wildbase Hospital at Massey University on July 17, 2026. - This is the first native resident bird to test positive. It is a wild bird of prey that likely got infected by hunting, eating, or scavenging infected birds. It showed neurological signs (wobbly on its feet, dull, weak) and was euthanized. - The Department of Conservation (DOC) has initiated emergency wildlife vaccinations for 300 core breeding birds of highly endangered species (67 birds have received their first dose as of mid-July). This is a dramatic and rare public health/conservation response! - Advice to poultry farmers has changed: MPI now officially supports free-range farmers temporarily housing their birds indoors to protect them. 2. Let's see if we have an existing slug for H5N1 in Australia/Oceania. - Yes! We have: - `h5n1-avian-influenza-arrival-australia` ("H5N1 Avian Influenza Arrives in Australia with Detections in Wild Seabirds") - `australia-h5n1-wildlife-transmission` ("Australia H5N1 Escalation: First Case Confirmed in Local Native Seabird on Mainland") - `h5n1-avian-influenza-australia-local-transmission` ("H5N1 Bird Flu Jumps to Local Australian Wildlife with First Native Seabird Case") - `australia-h5n1-avian-influenza-wild-birds-nsw-east-coast-expansion` - `australia-h5n1-avian-influenza-seabirds` - Wait, since H5N1 has now officially arrived in New Zealand and represents a highly consequential jump to Oceania's native wildlife, we should write a new finding or update the most relevant one. Let's look at `h5n1-avian-influenza-arrival-australia` or create a broader finding for the Oceania region, or update `australia-h5n1-wildlife-transmission` / `h5n1-avian-influenza-arrival-australia`. Actually, New Zealand is a distinct country and is a massive step. Let's create a dedicated finding for H5N1's arrival in New Zealand: `h5n1-avian-influenza-arrival-new-zealand`. Or we can update `h5n1-avian-influenza-arrival-australia` but rename/refocus it, or just create a new note `h5n1-avian-influenza-arrival-new-zealand` since it's a completely new country and has its own distinct emergency wildlife vaccination campaign and poultry guidelines. Let's write a dedicated note `h5n1-avian-influenza-arrival-new-zealand`! Wait, let's also check if there are other updates on the New World Screwworm outbreak in the US Southwest. Let's search for "New World screwworm" and check if there are recent updates in the last week. This is watch `019ec32d-6d1a-725d-9d28-251b38e8d928` or finding `new-world-screwworm-us-outbreak`. Let's search.

Wait, let's look at the Virginia Department of Health "Situation Update" from July 17, 2026. It says: "The USDA reported 5 New World Screwworm detections in the past week, bringing the total to 39 detections. All new detections were in Texas livestock." Let's fetch this PDF or look for articles that summarize the latest New World Screwworm detections. This is an excellent, extremely precise, and fresh update for `new-world-screwworm-us-outbreak`! Let's search for "New World screwworm 39 detections" or "New World screwworm Texas Zavala County" to see if we can get a web page with this information. Or let's search for the Hill article on Rollins (Agriculture Sec.) or other articles about screwworm. Let's do a search.

This is phenomenal! Let's analyze the New World Screwworm updates: 1. **Total Cases**: As of July 16, 2026, the USDA has confirmed **39 New World screwworm infestations** (38 in Texas, 1 in New Mexico). 2. **Slowing Down**: Cases are showing signs of slowing down in July. Texas has reported only 4 new cases in July so far, compared to 31 in June. For the first time, inactive cases outnumber active ones, signaling that containment efforts are working. 3. **Quarantine Zone**: Texas has established a massive quarantine zone as screwworm detections rise. 4. **International Impact**: Canada has suspended the importation of certain animals from Texas due to the New World Screwworm, and animals from other states must have a USDA Accredited Veterinarian provide an NWS Certification Statement. This shows real economic and trade consequences! 5. This is a perfect update for `new-world-screwworm-us-outbreak` ("New World Screwworm Southwest Outbreak Triggers CDC Emergency Operations Center Activation"). Let's fetch the Texas Public Radio (TPR) article or the USA Today/Yahoo News article to get precise quotes. Let's fetch the TPR article `https://www.tpr.org/public-health/2026-07-03/31-confirmed-new-world-screwworm-infestations-texas-tracker-and-what-you-need-to-know`. This is perfect! Let's do a fetch.

Ah! The search budget is spent, which is perfectly fine because we have already gathered extremely rich, primary, and fresh evidence on three major fronts: 1. **The Post-Makary FDA Pivot / Reversals & Resubmissions**: We have detailed information about Saol Therapeutics' resubmission of SL1009 (DCA) in PDCD on June 30, 2026 (announced July 7, 2026). We also have the upcoming Cellular, Tissue, and Gene Therapies Advisory Committee meetings for Capricor's deramiocel (July 29, 2026) and Replimune's RP1 (July 30, 2026). This is a perfect update for `fda-regulatory-pivot-advisory-committees-capricor-replimune`. 2. **FDA CRL Transparency Policy Resumption**: The FDA has resumed its controversial policy of releasing Complete Response Letters (CRLs) in real-time. After a 3-month pause starting in April 2026 (triggered by an undisclosed pharmaceutical company's citizen's petition via Covington & Burling), the FDA released a batch of 14 CRLs on July 10, 2026, and confirmed on July 14, 2026, that the pause has been lifted. This is a brand new, highly significant policy finding: `fda-crl-public-disclosure-policy`. 3. **H5N1 Bird Flu's Arrival in New Zealand**: New Zealand has confirmed its first two cases of H5N1. The first was in a migratory brown skua at Petone Beach, Wellington (announced mid-July), and the second was in a native resident kāhu (swamp harrier hawk) in Wairarapa on July 17, 2026. This has triggered an emergency wildlife vaccination campaign by the Department of Conservation (DOC) and a shift in advice for poultry farmers. This is a brand new finding: `h5n1-avian-influenza-arrival-new-zealand`. 4. **New World Screwworm Outbreak**: The US Southwest outbreak has reached 39 confirmed infestations (38 in Texas, 1 in New Mexico) as of July 16, 2026. While cases are slowing down in July (only 4 new cases compared to 31 in June, and inactive cases outnumber active ones for the first time), Texas has established a massive quarantine zone, and Canada has suspended certain animal imports from Texas. This is a perfect update for `new-world-screwworm-us-outbreak`. This is incredibly rich and directly addresses multiple active watches! Let's review the active watches and see if we can resolve or update them: - **FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting for Capricor's deramiocel in DMD cardiomyopathy** (`019f061f-f34a-7079-a276-d216329928b2`): This is scheduled for July 29, 2026. It hasn't happened yet, but we've updated its status. We'll keep it open. - **FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma** (`019f0620-007b-7dab-87b4-0363a2496ea1`): This is scheduled for July 30, 2026, with a PDUFA date of August 2, 2026. We'll keep it open. - **FDA filing acceptance and PDUFA date for Saol's SL1009** (`019f67f8-1a98-7a61-a210-07071f61b308`): The resubmission occurred on June 30, 2026. The FDA's filing acceptance decision and PDUFA date assignment are expected by prior to July 30, 2026. We'll keep it open. - **Australia H5N1 transmission to poultry or local wildlife** (`019f2f50-7f4d-7361-8f05-cdf170c2d727`): This is an ongoing watch. We have noted that Australia's bird flu cases in migratory seabirds have increased to 17, and a stranded humpback whale is being tested. We'll keep it open. Wait, let's write our findings now! Let's structure each finding note properly, ensuring we name and link the actual sources, carry 1-2 representative verbatim quotes, and explain what they mean. Let's write the first note: `fda-regulatory-pivot-advisory-committees-capricor-replimune`. Wait, let's review the existing note content for `fda-regulatory-pivot-advisory-committees-capricor-replimune` from `read_notes` preview: "The U.S. Food and Drug Administration (FDA), under acting Commissioner Kyle Diamantas, is undergoing a profound operational and regulatory shift. Following the exit of former Commissioner Marty..." Let's write a complete update to this note. We'll include: - The upcoming CTGT Advisory Committee meeting on July 29, 2026, for Capricor's deramiocel (BLA 125842). - The upcoming CTGT Advisory Committee meeting on July 30, 2026, for Replimune's RP1, followed immediately by its PDUFA date on August 2, 2026. - Saol Therapeutics' resubmission of SL1009 (DCA) on June 30, 2026 (announced July 7, 2026) following constructive Type A and Type C meetings where the FDA allowed resubmission with additional survival analyses of existing data rather than a new trial. - The broader trend of "post-Makary FDA reversals" (including uniQure and REGENXBIO). - The leadership vacuum at the FDA post-Makary. Let's write this update first. Let's draft the body carefully. No frontmatter YAML. The title is the first `# ` heading. Let's call `write_note`.

Now let's write a dedicated note on the FDA's Complete Response Letter (CRL) transparency policy: `fda-crl-public-disclosure-policy`. This tracks the policy's launch, the April 2026 pause due to a Covington & Burling citizen's petition on behalf of an undisclosed pharma company, the July 10, 2026 drop of 14 CRLs, and the subsequent July 14, 2026 confirmation that the policy has resumed. This is a highly significant regulatory policy finding that is completely new. Let's call `write_note` for this.

Now let's write a dedicated note on the arrival of H5N1 avian influenza in New Zealand: `h5n1-avian-influenza-arrival-new-zealand`. This is a brand new, highly consequential development. We'll detail: - The first confirmed case in a migratory brown skua at Petone Beach, Wellington (around July 10-15, 2026). - The second confirmed case, which is the first native resident bird: a kāhu (swamp harrier hawk) found near Carterton in Wairarapa on July 17, 2026. - The hawk showed neurological symptoms and was euthanized at Massey University's Wildbase Hospital. - The Department of Conservation (DOC) starting a landmark preventive vaccination campaign for 300 core breeding birds of highly endangered species (67 vaccinated as of mid-July). - The shift in poultry guidelines, with the Ministry for Primary Industries (MPI) supporting free-range farmers to temporarily house birds indoors. - The broader regional context of Australia's recent detections increasing to 17. Let's call `write_note` for this.

Now let's update the New World Screwworm note: `new-world-screwworm-us-outbreak`. Let's see what the preview of the existing note is: "The outbreak of the highly destructive, flesh-eating parasite **New World screwworm** (*Cochliomyia hominivorax*) in the U.S. Southwest has escalated into a high-priority public health, agricultural,..." Let's write a complete update to this note. We'll include: - The updated case count: 39 confirmed infestations as of July 16, 2026 (38 in Texas, 1 in New Mexico). - The recent detections: 2 infestations confirmed on July 14, 2026, in sheep in Pecos County, Texas. - The slowing trend: only 4 new cases reported in Texas in July so far, compared to 31 in June. Inactive cases outnumber active ones for the first time, suggesting containment efforts are showing success. - Texas establishing a massive quarantine zone. - Canada suspending the importation of certain animals from Texas due to the outbreak, and requiring NWS certification statements for animals imported from other US states. Let's call `write_note` for this.

This is brilliant! Now, let's double check if we need to open any new threads or register any new watches. Looking at our findings, we have: 1. The FDA's Complete Response Letter (CRL) transparency policy has resumed. We should monitor this. Is there a future dated catalyst or is it ongoing? It's an ongoing policy process. We can register an ongoing tripwire or watch for the finalization of the proposed rule (RIN 0910-AJ16) which is a major regulatory milestone. Let's register a watch for the finalization of the proposed rule RIN 0910-AJ16 regarding the public release of CRLs. This is forward-looking and very specific! 2. For H5N1 in New Zealand: We should register a watch to monitor whether H5N1 spreads to commercial poultry flocks, native wildlife sanctuaries (like Pūkaha Mount Bruce), or native marine mammals in New Zealand. This is an ongoing watch of cardinality `ongoing`. Let's register these watches using `record_watch`. First, let's register the watch for the FDA's proposed rule RIN 0910-AJ16. Let's make it `one_shot` or `ongoing`? Rule finalization is a one-shot event. Let's set it as `one_shot` with a target date of late 2026 or early 2027. Let's set `fire_date` to `2027-03-31T00:00:00Z` or similar. Let's do `one_shot`.

Now let's register the watch for H5N1 transmission in New Zealand. Let's call `record_watch` for `h5n1-avian-influenza-arrival-new-zealand` with cardinality `ongoing`. It will monitor whether H5N1 spreads to New Zealand's commercial poultry flocks or native wildlife sanctuaries (like Pūkaha Mount Bruce). This is highly aligned with the regional biosecurity threat! Let's do this.

Excellent! Let's see if there are any other watches or threads we need to record or resolve. Wait, let's review the threads: - `019f67f8-1a98-7a61-a210-07071f61b308` (FDA filing acceptance and PDUFA date for Saol's SL1009) -> This is still open because the FDA has not accepted it yet (expected prior to July 30). - `019f061f-f34a-7079-a276-d216329928b2` (FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy) -> Still open (scheduled for July 29). - `019f0620-007b-7dab-87b4-0363a2496ea1` (FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma) -> Still open (scheduled for July 30). - `019f2f50-7f4d-7361-8f05-cdf170c2d727` (Australia H5N1 transmission to poultry or local wildlife) -> Still open and ongoing. Everything is perfectly aligned. We can now call `finish_cycle`. I will call the `finish_cycle` tool to conclude this research cycle.

I have completed this research cycle, delivering highly consequential updates and two new dedicated findings. ### Key Researched Updates and Findings 1. **FDA Resumes Controversial Complete Response Letter (CRL) Transparency Policy** `[[fda-crl-public-disclosure-policy]]` *(New Finding)* * **What Happened**: After a three-month pause triggered by an undisclosed pharmaceutical company's citizen's petition (filed by Covington & Burling in April 2026), the FDA has resumed its "radical transparency" policy of releasing drug rejection letters (CRLs) in real-time. * **Key Evidence**: On July 10, 2026, the FDA dropped a new tranche of 14 CRLs (including rejections for Grace Therapeutics and the Hengrui/Elevar liver cancer combo). On July 14, 2026, HHS officially confirmed the pause is lifted and the FDA is "strengthening and formalizing its internal processes" to proactively publish redacted CRLs. * **Next Steps**: The FDA is working to formalize this process via a proposed rule (RIN 0910-AJ16) that would eliminate the presumption of commercial confidentiality for unapproved marketing applications. I registered a **new watch** to monitor the finalization of this rule. 2. **H5N1 Avian Influenza Official Arrival in New Zealand** `[[h5n1-avian-influenza-arrival-new-zealand]]` *(New Finding)* * **What Happened**: Highly pathogenic H5N1 has officially breached New Zealand's borders, ending its status as one of the last continental strongholds free of the virus. * **Key Evidence**: Following a first case in a migratory brown skua on Petone Beach, Wellington, Biosecurity Minister Andrew Hoggard confirmed on **July 17, 2026**, a second case in a native resident **kāhu (swamp harrier hawk)** near Carterton in Wairarapa. The hawk exhibited severe neurological symptoms and was euthanized. This confirms local transmission/scavenging on the mainland. * **Conservation Response**: The Department of Conservation (DOC) launched a high-stakes emergency vaccination campaign for 300 core breeding birds of critically endangered species (67 vaccinated as of mid-July). MPI has also shifted guidelines, supporting free-range poultry farmers to temporarily house birds indoors. I registered a **new watch** to monitor potential transmission to commercial poultry or wildlife sanctuaries (e.g., Pūkaha Mount Bruce). 3. **The "Post-Makary" FDA Pivot: Saol's SL1009 Resubmission and Upcoming AdComms** `[[fda-regulatory-pivot-advisory-committees-capricor-replimune]]` *(Updated)* * **What Happened**: The regulatory U-turns and resubmissions following the spring departures of Marty Makary and Vinay Prasad continue to accelerate. * **Key Evidence**: On June 30, 2026 (announced July 7, 2026), Saol Therapeutics resubmitted its NDA for **SL1009 (DCA)** in pyruvate dehydrogenase complex deficiency (PDCD) after constructive Type A and Type C meetings. The FDA applied regulatory flexibility, allowing Saol to directly resubmit using additional survival analyses of existing data (showing a 91% reduction in risk of death) rather than demanding a new clinical trial. * **Upcoming Dates**: High-stakes Cellular, Tissue, and Gene Therapies Advisory Committee meetings are now officially scheduled for **Capricor's deramiocel** (July 29, 2026) and **Replimune's RP1** (July 30, 2026), with the latter's PDUFA date arriving on August 2, 2026. This is accompanied by an "unprecedented" post-Makary leadership vacuum at the agency. 4. **New World Screwworm Outbreak Hits 39 Cases Amid Quarantine and Trade Bans** `[[new-world-screwworm-us-outbreak]]` *(Updated)* * **What Happened**: The Southwest flesh-eating parasite outbreak has reached 39 confirmed infestations (38 in Texas, 1 in New Mexico) as of July 16, 2026, with the latest cases confirmed in Pecos County sheep on July 14. * **Key Evidence**: While cases are slowing down (only 4 new cases in July compared to 31 in June, with inactive cases outnumbering active ones for the first time), Texas has established a massive quarantine zone. * **Trade Fallout**: Canada has suspended the importation of certain animals from Texas and instituted strict USDA-accredited NWS certification requirements for imports from all other U.S. states.